Salunke Abhijeet Ashok, Nandy Kunal, Pathak Subodh Kumar, Shah Jaymin, Kamani Mayur, Kottakota Viswanth, Thivari Praveen, Pandey Apurva, Patel Keval, Rathod Priyank, Bhatt Supreet, Dave Pariseema, Pandya Shashank
Department of Surgical Oncology, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India.
Department of Surgical Oncology, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India.
Diabetes Metab Syndr. 2020 Sep-Oct;14(5):1431-1437. doi: 10.1016/j.dsx.2020.07.037. Epub 2020 Jul 28.
Currently there is limited knowledge on cancer and COVID-19; we conducted a systematic review and meta-analysis to evaluate the impact of cancer on serious events including ICU admission rate and mortality in COVID 19.
PubMed, Cochrane Central Register of Clinical Trials were searched on April 16, 2020, to extract published articles that reported the outcomes of cancer in COVID-19 patients. The search terms were "coronavirus" and "clinical characteristics" with no language or time restrictions. We identified 512 published results and 13 studies were included in the analysis.
There were 3775 patients, of whom 63 (1·66%) had a cancer. The pooled estimates of ICU admission in COVID 19 patients with and without cancer were 40% versus 8·42%.The odds ratio of ICU admission rates between the cancer and non-cancer groups was 2.88 with a 95% CI of 1·18 to 7·01 (p = 0·026). The pooled estimates of death rate in COVID -19 patients with and without cancer were 20·83% versus 7·82%. The odds ratio of death rates between the cancer and non-cancer groups was 2.25 with a 95% CI ranging from 0·71 to 7·10 with p value of 0·166. The pooled prevalence of cancer patients was 2% (95 CI 1-4).
Presence of cancer in COVID-19 leads to higher risk of developing serious events i.e. ICU admission, mechanical ventilation and mortality. The presence of cancer has a significant impact on mortality rate in COVID-19 patients.
背景与目的
目前关于癌症与新型冠状病毒肺炎（COVID-19）的相关知识有限；我们进行了一项系统综述和荟萃分析，以评估癌症对包括入住重症监护病房（ICU）率和COVID-19死亡率在内的严重事件的影响。
于2020年4月16日检索了PubMed、Cochrane临床试验中心注册库，以提取报告COVID-19患者癌症结局的已发表文章。检索词为“冠状病毒”和“临床特征”，无语言或时间限制。我们确定了512条已发表结果，其中13项研究纳入分析。
共有3775例患者，其中63例（1.66%）患有癌症。患有癌症和未患癌症的COVID-19患者入住ICU的合并估计率分别为40%和8.42%。癌症组与非癌症组入住ICU率的比值比为2.88，95%置信区间为1.18至7.01（p = 0.026）。患有癌症和未患癌症的COVID-19患者死亡率的合并估计率分别为20.83%和7.82%。癌症组与非癌症组死亡率的比值比为2.25，95%置信区间为0.71至7.10，p值为0.166。癌症患者的合并患病率为2%（95%置信区间1%-4%）。
COVID-19患者中患有癌症会导致发生严重事件（即入住ICU、机械通气和死亡）的风险更高。癌症的存在对COVID-19患者的死亡率有显著影响。
